Exploring possibilities towards PeRsonalIsed MEdicine in Rheumatoid Arthritis (PRIMERA): tailored modifications to standard treat-to-target management—a multicentre, randomised, open-label trial
Authors' conclusion
Modifying the standard treat-to-target strategy, by stratifying the initial DMARD according to autoantibody status combined with rapidly intensifying therapy based on early treatment response, did not result in superior clinical outcomes.
Study context
- Population
- Adults with disease-modifying antirheumatic drug (DMARD)-naïve rheumatoid arthritis (RA) (2010 ACR/EULAR criteria)
- Participants
- 308 adults
- Comparison
- Tailor-made approach vs routine care
- Primary endpoint
- Two primary outcomes: ts/bDMARD use at 10 months and mean DAS over time; superiority required both to favour the tailor-made approach
- Follow-up
- 10 months
Methodological detailsmulticentre, open-label, 1:1 randomisation, treat-to-target
- Multicentre
- Open-label
- 1:1 randomisation
- Treat-to-target
Primary result
As reported in the abstract
ts/bDMARD use
One-sided p=0.20
Further findings
| Outcome | P value |
|---|---|
| Co-primary: mean DAS over timeTailor-made vs Routine care | P = 0.57 |
Co-primary: mean Disease Activity Score (DAS) over time
- Mean DAS trajectories were similar
Patient-reported outcome measure trajectories
- No differences in mean PROM trajectories
Safety
Adverse events
- No differences observed
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Exploring possibilities towards PeRsonalIsed MEdicine in Rheumatoid Arthritis (PRIMERA): tailored modifications to standard treat-to-target management—a multicentre, randomised, open-label trial. RMD Open. Published 20 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →